S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10

COMPASS Pathways Stock Forecast, Price & News

+3.58 (+10.14 %)
(As of 10/22/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume686,852 shs
Average Volume403,201 shs
Market Capitalization$1.62 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CMPS News and Ratings via Email

Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter.

COMPASS Pathways logo

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$5.65 per share


Net Income
$-60.33 million




Market Cap
$1.62 billion
Next Earnings Date
11/11/2021 (Estimated)
Not Optionable


Overall MarketRank

1.70 out of 5 stars

Medical Sector

912th out of 1,358 stocks

Pharmaceutical Preparations Industry

448th out of 666 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

COMPASS Pathways (NASDAQ:CMPS) Frequently Asked Questions

Is COMPASS Pathways a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" COMPASS Pathways stock.
View analyst ratings for COMPASS Pathways
or view top-rated stocks.

What stocks does MarketBeat like better than COMPASS Pathways?

Wall Street analysts have given COMPASS Pathways a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but COMPASS Pathways wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting COMPASS Pathways?

COMPASS Pathways saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 561,300 shares, an increase of 37.9% from the August 31st total of 406,900 shares. Based on an average trading volume of 361,400 shares, the short-interest ratio is currently 1.6 days.
View COMPASS Pathways' Short Interest

When is COMPASS Pathways' next earnings date?

COMPASS Pathways is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for COMPASS Pathways

How were COMPASS Pathways' earnings last quarter?

COMPASS Pathways plc (NASDAQ:CMPS) issued its quarterly earnings data on Tuesday, August, 10th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.11.
View COMPASS Pathways' earnings history

What price target have analysts set for CMPS?

6 equities research analysts have issued 12-month price targets for COMPASS Pathways' stock. Their forecasts range from $50.00 to $100.00. On average, they expect COMPASS Pathways' stock price to reach $74.33 in the next twelve months. This suggests a possible upside of 91.1% from the stock's current price.
View analysts' price targets for COMPASS Pathways
or view top-rated stocks among Wall Street analysts.

Who are COMPASS Pathways' key executives?

COMPASS Pathways' management team includes the following people:
  • Mr. George Jay Goldsmith, Co-Founder, Chair of the Board & CEO (Age 67, Pay $722.79k)
  • Mr. Lars Christian Wilde, Co-Founder, Pres & Chief Bus. Officer (Age 35)
  • Dr. Ekaterina Malievskaia M.D., Co-Founder, Chief Innovation Officer & Director (Age 54, Pay $536.4k)
  • Mr. Piers John Morgan, Chief Financial Officer (Age 55)
  • Mr. Nate Poulsen J.D., Gen. Counsel & Chief Legal Officer (Age 42)
  • Mr. Stephen D. Schultz, Sr. VP of Investor Relations
  • Ms. Tracy Cheung, Chief Communications Officer
  • Mr. Marco Mohwinckel, Chief Commercial Officer
  • Mr. Trevor Mill, Chief Devel. Officer
  • Dr. Greg Ryslik Ph.D., Sr. VP of Data Science, Machine Learning & Digital Health Research

What other stocks do shareholders of COMPASS Pathways own?

Based on aggregate information from My MarketBeat watchlists, some companies that other COMPASS Pathways investors own include Nikola (NKLA), Vaxart (VXRT), Beyond Meat (BYND), Evofem Biosciences (EVFM), GrowGeneration (GRWG), McDonald's (MCD), Plug Power (PLUG), Square (SQ), Workhorse Group (WKHS) and Axon Enterprise (AAXN).

When did COMPASS Pathways IPO?

(CMPS) raised $100 million in an initial public offering on Friday, September 18th 2020. The company issued 6,700,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is COMPASS Pathways' stock symbol?

COMPASS Pathways trades on the NASDAQ under the ticker symbol "CMPS."

Who are COMPASS Pathways' major shareholders?

COMPASS Pathways' stock is owned by a variety of institutional and retail investors. Top institutional investors include Belvedere Trading LLC (0.09%), Kestra Private Wealth Services LLC (0.02%) and Koshinski Asset Management Inc. (0.01%).

Which institutional investors are selling COMPASS Pathways stock?

CMPS stock was sold by a variety of institutional investors in the last quarter, including Kestra Private Wealth Services LLC.

Which institutional investors are buying COMPASS Pathways stock?

CMPS stock was acquired by a variety of institutional investors in the last quarter, including Belvedere Trading LLC, and Koshinski Asset Management Inc..

How do I buy shares of COMPASS Pathways?

Shares of CMPS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is COMPASS Pathways' stock price today?

One share of CMPS stock can currently be purchased for approximately $38.89.

How much money does COMPASS Pathways make?

COMPASS Pathways has a market capitalization of $1.62 billion. The company earns $-60.33 million in net income (profit) each year or ($3.55) on an earnings per share basis.

How many employees does COMPASS Pathways have?

COMPASS Pathways employs 2,020 workers across the globe.

What is COMPASS Pathways' official website?

The official website for COMPASS Pathways is www.compasspathways.com.

How can I contact COMPASS Pathways?

The company can be reached via phone at 1-646-905-3974 or via email at [email protected].

This page was last updated on 10/23/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.